Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis

被引：25

作者：

Christodoulakos, G ^{[1
]}

Panoulis, C ^{[1
]}

Kouskouni, E ^{[1
]}

Chondros, C ^{[1
]}

Dendrinos, S ^{[1
]}

Creatsas, G ^{[1
]}

机构：

[1] Univ Athens, Aretaeion Hosp, Dept Obstet & Gynecol 2, Athens, Greece

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2002年 / 16卷 / 01期

关键词：

menopause; HRT; raloxifene; endothelin-1; nitric oxide; prostacyclin; cardiovascular disease;

D O I：

10.1080/713602991

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This randomized double-blind study was conducted to investigate the effects of 17beta-estradiol plus norethisterone acetate, and raloxifene, on nitric oxide (NO), prostacyclin (PGI(2)) and endothelin-1 (ET-1) serum levels in postmenopausal women. Treatment was initiated after a 28-50 day placebo period. Fourteen women were treated daily with 17beta-estradiol 2 mg plus norethisterone acetate 1 mg (E-2 + NETA), and 14 with raloxifene HCl 60 mg for a period of 6 months. Serum NO, PGI(2) and ET-1 levels were estimated at baseline, after placebo, and at months 3 and 6. E-2 + NETA decreased NO levels significantly, while raloxifene did not cause any appreciable change. Both regimens decreased PGI(2) levels and ET-1 levels significantly. Finally, E-2 + NETA and raloxifene increased the NO/ET-1 ratio by 61.4% and 81.1 %, respectively. In conclusion, both regimens may exert a cardio-protective effect by decreasing ET-1 levels and increasing the NO/ET-1 ratio. In contrast, both regimens had a negative influence on PGI(2) levels.

引用

页码：9 / 17

页数：9

共 43 条

[11] Endothelin plasma levels in primary amenorrheic adolescents before and after estrogen treatment [J].

Creatsas, GC ;

MalamitsiPuchner, AB ;

Hassan, EA ;

Economou, EB ;

Aravantinos, DI .

JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 1996, 3 (06) :350-353

[12] ACUTE VASCULAR EFFECTS OF ESTROGEN IN POSTMENOPAUSAL WOMEN [J].

GILLIGAN, DM ;

BADAR, DM ;

PANZA, JA ;

QUYYUMI, AA ;

CANNON, RO .

CIRCULATION, 1994, 90 (02) :786-791

[13] EFFECTS OF PHYSIOLOGICAL LEVELS OF ESTROGEN ON CORONARY VASOMOTOR FUNCTION IN POSTMENOPAUSAL WOMEN [J].

GILLIGAN, DM ;

QUYYUMI, AA ;

CANNON, RO ;

JOHNSON, GB ;

SCHENKE, WH .

CIRCULATION, 1994, 89 (06) :2545-2551

[14]

GYETTA V, 1997, CIRCULATION, V96, P2795

[15] Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women [J].

Herrington, DM ;

Pusser, BE ;

Riley, WA ;

Thuren, TY ;

Brosnihan, KB ;

Brinton, EA ;

MacLean, DB .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) :1606-1612

[16] Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].

Hulley, S ;

Grady, D ;

Bush, T ;

Furberg, C ;

Herrington, D ;

Riggs, B ;

Vittinghoff, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613

[17] Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate [J].

Imthurn, B ;

Rosselli, M ;

Jaeger, AW ;

Keller, PJ ;

Dubey, RK .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :388-394

[18]

Kearney C E, 1998, Climacteric, V1, P143, DOI 10.3109/13697139809085530

[19]

LIEBERMAN EH, 1994, ANNI NTERN MED, V12, P934

[20]

Lobo RA, 1998, INT CONGR SER, V1183, P555

← 1 2 3 4 5 →